Loading…
Company announces positive preliminary results from in vitro study.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced that its drug candidate has shown early signals of benefit in Alzheimer's patient-derived neurons. The results were derived from an in vitro study conducted on neurons from Alzheimer's patients.
The company did not provide specific numerical data or comparisons in this announcement. The study is part of ongoing research to evaluate the potential therapeutic effects of the drug candidate.
As of the latest available data, NeuroSense Therapeutics has a free float of 13,767,800 shares and 29,551,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.